MeiraGTx Holdings plc appointed Alan M. Sebulsky to its board effective September 23, with his term running until the 2028 annual meeting and service on the Science and Technology Committee. The appointment matters to investors because Sebulsky’s background includes work with a biopharmaceutical portfolio exceeding $2 billion.
Key Highlights
- Alan M. Sebulsky joined MeiraGTx’s board effective September 23.
- His board term runs until the company’s 2028 annual meeting.
- Sebulsky previously worked with a biopharmaceutical portfolio worth over $2 billion.
MeiraGTx Holdings plc (NASDAQ: MGTX) is a biotechnology company. Alan M. Sebulsky joined its board effective September 23, with his term extending until the 2028 annual meeting of shareholders. He will also serve on the Science and Technology Committee.
Board Term and Director Arrangements
The board approved the appointment on September 22 following a recommendation from its Nominating and Corporate Governance Committee. Senior management recommended Sebulsky as a potential board candidate. Sebulsky is eligible for compensation under MeiraGTx’s Non-Employee Director Compensation Program and is expected to enter the company’s standard indemnification agreement for directors and officers. The company said there are no related-party transactions between MeiraGTx and Sebulsky.
Biopharmaceutical Investment Experience
Sebulsky’s earlier work included Portfolio Management at BBT Capital Management Advisory LLC and investment roles at Lincoln Capital Management.
FAQs
Q: Who joined the MeiraGTx board?
A: Alan M. Sebulsky joined the MeiraGTx board. He was appointed effective September 23 and will serve until the 2028 annual meeting of shareholders.
Q: What committee will Alan M. Sebulsky serve on at MeiraGTx?
A: Sebulsky will serve as a member of MeiraGTx’s Science and Technology Committee. The appointment accompanies his new board role at the company.
Q: When did MeiraGTx appoint Alan M. Sebulsky, and when did the appointment become effective?
A: The filing says the Board appointed him on September 22, 2026. His appointment became effective on September 23, 2026, as director.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.